Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Journal Articles

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Maha M Kamel, Monika Kutyna, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2023-188340

Published: 2023

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation

Yanjing Vera Liu, Jeremiah Suryatenggara, Hannan Wong, Jing Ping Tang, Hong Kee Tan, Junsu Kwon, Qiling Zhou, Simone Ummarino, Alexander Ebralidze, John G. Doench, Li Chai, Touati Benoukraf, Devendra Hiwase, Daniel Thomas, Annalisa Di Ruscio, Daniel G. Tenen, Mahmoud Adel Bassal

Blood (2023) 142 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2023-182715

Published: 2023

Journal Articles

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Monika Kutyna, Maha M Kamel, David M. Ross, Agnes S. M. Yong, Chun Yew Fong, Chloe Thompson-Peach, Steven W. Lane, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2023-179706

Published: 2023

Journal Articles

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Devendra Hiwase, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2023-179688

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood (2022) 140 (Supplement 1): 9798–9799.

https://doi.org/10.1182/blood-2022-165859

Published: 2022

Journal Articles

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Monika M Kutyna, Chung Hoow Kok, Yoon Lim, David Campbell, Sharon Paton, Chloe AL Thompson-Peach, Kelly SY Lim, Timothy Hughes, Sharad Kumar, Daniel Thomas, Stan Gronthos, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 9755–9756.

https://doi.org/10.1182/blood-2022-167994

Published: 2022

Journal Articles

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Niklas Landberg, Thomas Koehnke, Yusuke Nakauchi, Amy Fan, Daiki Karigane, Daniel Thomas, Ravindra Majeti

Blood (2022) 140 (Supplement 1): 2234–2235.

https://doi.org/10.1182/blood-2022-159617

Published: 2022

Journal Articles

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood (2022) 140 (Supplement 1): 6964–6965.

https://doi.org/10.1182/blood-2022-168349

Published: 2022

Journal Articles

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 6962–6963.

https://doi.org/10.1182/blood-2022-167978

Published: 2022

Journal Articles

Hypoxia and low temperature upregulate transferrin to induce hypercoagulability at high altitude

Blood (2022) 140 (19): 2063–2075.

https://doi.org/10.1182/blood.2022016410

Published: 2022

Includes: Supplemental data

Journal Articles

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia

Blood (2022) 139 (26): 3737–3751.

https://doi.org/10.1182/blood.2021013277

Published: 2022

Includes: Supplemental data

Journal Articles

Machine learning finds new AML subtypes

Daniel Thomas

Blood (2021) 138 (19): 1790–1792.

https://doi.org/10.1182/blood.2021012455

Published: 2021

Journal Articles

Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms

Monika M Kutyna, Chung Hoow Kok, Sharon Paton, Dimitrios Cakouros, Agnieszka Arthur, Timothy P. Hughes, Daniel Thomas, David Campbell, Stan Gronthos, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2021-148215

Published: 2021

Journal Articles

Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome

Christopher N Hahn, Simone K. Feurstein, Deepak Singhal, Monika M Kutyna, Rakchha Chhetri, Amilia Wee, Daniel Thomas, Hamish S Scott, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2021-154514

Published: 2021

Journal Articles

A Calreticulin Neoepitope-Directed Monoclonal Antibody Can Overcome JAK Inhibitor Resistance and Block TPO-Independent Megakaryocyte Differentation

Denis Tvorogov, Chloe AL Thompson-Peach, Johannes Foßelteder, Mara Dottore, Frank Stomski, Kelly SY Lim, Suraiya A Onnesha, David M Ross, Andreas Reinisch, Daniel Thomas, Angel F. Lopez

Blood (2021) 138 (Supplement 1): 3597.

https://doi.org/10.1182/blood-2021-154332

Published: 2021

Journal Articles

Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups

Rakchha Chhetri, Kirsty Sharplin, William Proudman, Monika M Kutyna, Siddarth Nayar, Deepak Singhal, David M Ross, Michelle Damin, Akash Kalro, Peter G Bardy, Daniel Thomas, Mithun V. Shah, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2021-154094

Published: 2021

NARROW

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Hypoxia and low temperature upregulate transferrin to induce hypercoagulability at high altitude

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia

Machine learning finds new AML subtypes

Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms

Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome

A Calreticulin Neoepitope-Directed Monoclonal Antibody Can Overcome JAK Inhibitor Resistance and Block TPO-Independent Megakaryocyte Differentation

Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only